Access expired on Monday, July 31, 2023
This content was originally shared by a registered user, but access has expired. Create a free account to gain permanent access to all PracticeUpdate content.
Already Have An Account? Log in Now
featured
Dara-CVRd as Induction and Extended Consolidation Improves Outcomes in Patients With Ultra–High-Risk Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma
J. Clin. Oncol 2023 Jun 14;[EPub Ahead of Print], MF Kaiser, A Hall, K Walker, A Sherborne, RM De Tute, N Newnham, S Roberts, E Ingleson, K Bowles, M Garg, A Lokare, C Messiou, RS Houlston, G Jackson, G Cook, G Pratt, RG Owen, MT Drayson, SR Brown, MW JennerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.